No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Shareholder Hengfeng Investment of zhejiang xinguang pharmaceutical (300519.SZ) plans to reduce its shareholding by no more than 2%.
Zhejiang Xinguang Pharmaceutical (300519.SZ) announced that the company's shareholder, Shengzhou Hefeng Investment Co., Ltd. (referred to as "Hefeng...")
Xinguang Pharmaceutical: Report for the third quarter of 2024
What Zhejiang Xinguang Pharmaceutical Co., Ltd.'s (SZSE:300519) 57% Share Price Gain Is Not Telling You
Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519) Surges 34%; Retail Investors Who Own 40% Shares Profited Along With Insiders
Xinguang Pharmaceutical: 2024 Semi-Annual Report
Some Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519) Shareholders Look For Exit As Shares Take 26% Pounding
